The startup has developed a tissue anchor system utilizing micro-needle technology with angled microneedles that penetrate the skin painlessly for intradermal drug and vaccine delivery. This approach provides healthcare professionals with a reliable alternative to traditional suturing methods, enhancing patient comfort and treatment efficacy.
Funding
Funding not disclosed
Founders
Product
Problem
Traditional intradermal injection techniques are challenging to administer consistently, leading to variable penetration depths, unreliable drug delivery, and potential damage to sensitive cells. Existing methods often result in uncontrolled skin compression, tenting, and leakage, limiting the volume and viscosity of injectables and increasing patient discomfort.
Solution
Pharmalatch has developed a platform technology for consistent and reliable intradermal drug and vaccine delivery, utilizing opposing arrays of angled microneedles. The device gently stretches the skin to prevent tenting and compression, ensuring complete needle penetration to a precise, pre-set depth of 820 μm. This approach enables healthcare professionals and patients to administer intradermal injections with greater accuracy and repeatability, unlocking the full potential of intradermal drug delivery for a wide range of therapies. The Pharma Latch platform supports various applications, from pre-clinical testing in small animals to HCP-administered clinical use and patient self-administration.
Target Audience
The primary target audience includes pharmaceutical companies developing vaccines, biologics, and cell therapies, as well as clinical researchers and healthcare providers seeking improved intradermal delivery methods.
Features
- Opposing arrays of intradermic microneedles with fixed length and angle for controlled skin stretching and penetration
- Precise, pre-set injection depth of 820 μm, ensuring consistent drug delivery to the dermal layer
- Unique fluid pathway and biomechanical manipulation of the skin to enable injection of high-volume (up to 3 mL) and high-viscosity (up to 60 cP) formulations
- Minimized injection back pressures and fluid shear stress to maintain cell viability during administration of cell-based therapies
- Device geometry governs injection depth, eliminating variability associated with user technique
- Platform technology adaptable to various device formats, including Pharma Latch Pico for pre-clinical research, Pharma Latch Hollow for clinical use, and Pharma Latch Self for patient self-administration
- Low dead volume design to minimize injectate waste, particularly beneficial for high-value applications